Effects of hypothyroidism on bronchial reactivity in non-asthmatic subjects

Siegfried Wieshammer, Fritz S Keck, Andreas C Schäuffelen, Helga von Beauvais, Herbert Seibold, Vinzenz Hombach

Abstract

The effect of hypothyroidism on non-specific bronchial reactivity was studied in 11 patients without pulmonary disease (mean age 40 (SD 13) years) who had had a total thyroidectomy and radioiodine treatment for thyroid cancer 41 (36) months before the study. All patients were studied on two occasions, once when mildly hyperthyroid while having long term thyroxine replacement treatment and once when hypothyroid two weeks after stopping triiodothyronine for the purpose of screening for metastases. Bronchial reactivity was assessed by measuring specific airways conductance (sGaw) after increasing doses of inhaled carbachol (45–1260 µg). The dose producing a 35% decrease in sGaw (PD35) was determined from the cumulative log dose–response curve by linear regression analysis. Mean baseline sGaw values were similar when the patients were hypothyroid and when they were hyperthyroid (1·35 (0·36) and 1·41 (0·56) s·1 kPa⁻¹). The interstudy coefficients of variation of baseline sGaw were higher in the thyroid patients than in a euthyroid control group (14% versus 8%). Geometric mean PD35 was lower when the patients were hypothyroid (97 µg) than when they were mildly hyperthyroid (192 µg). It is concluded that acute hypothyroidism increases non-specific bronchial reactivity in non-asthmatic subjects.

Several studies have shown an association between hyperthyroidism and increasing severity of asthma. Treatment of hyperthyroidism has been shown to improve asthma and to attenuate the bronchoconstrictor response of asthmatic patients to inhaled histamine, whereas replacement therapy in hypothyroid patients may cause asthma to deteriorate. These observations are surprising at first sight because many of the effects of thyroid hormone resemble the effects of stimulation of the sympathetic nervous system.

The relation between thyroid function and non-specific bronchial reactivity is less well defined in non-asthmatic subjects but there is no evidence that thyrotoxicosis is associated with bronchial hyperreactivity. Villa et al. reported an inverse relation between thyroid function and bronchial reactivity to inhaled carbachol in congenitally hypothyroid non-asthmatic children. We have measured the response to inhaled carbachol in patients who had had total thyroidectomy and radioiodine treatment for thyroid cancer while they were not having replacement treatment for medical reasons and when they were mildly hyperthyroid while having long term replacement treatment. Baseline specific airways conductance (sGaw) was also determined in a euthyroid control group on two occasions to assess the interstudy variation in measurements and to find out whether a change in thyroid state affects variation in measurements of sGaw.

Methods

STUDY GROUP

We studied five men and six women aged 20–55 years who had had total thyroidectomy and radioiodine treatment for thyroid cancer 41 (36) months before this study. The patients were maintained on long term therapy with thyroxine in a dosage slightly above replacement doses to suppress thyroid stimulating hormone secretion—that is, they were rendered mildly hyperthyroid. None was atopic or had evidence of pulmonary disease on the basis of history, clinical findings, chest radiograph, or results of pulmonary function tests. Only one patient smoked and except for thyroxine no drugs were being taken at the time of study. No patient had had an upper respiratory tract infection within one month of being tested. Patients with paralysis of the laryngeal nerve resulting from thyroid surgery were excluded from the study. The experimental character of this study was explained to each patient and informed consent was obtained.

STUDY DESIGN

All patients were studied on two occasions separated by 103 days on average—once while they were mildly hyperthyroid during long term replacement treatment and once while they were hypothyroid after their replacement treatment with thyroid hormones had been stopped to permit a scheduled follow up iodine-131 total body scan to screen for metastases. Thyroxine was changed to triiodothyronine five weeks before the hypothyroid study, which was carried out two weeks after triiodothyronine had been stopped. After completion of the hypothyroid study replacement treatment was started again. The hyperthyroid studies were performed when the patients had been mildly
hyperthyroid for at least six weeks. The two studies were carried out in random order. The operator was unaware of the hormonal state of the patients.

HORMONE ASSAYS
Serum concentrations of thyroxine, triiodothyronine, and thyroid stimulating hormone were measured by radioimmunoassay. Thyroxine and triiodothyronine uptake were measured to detect any alterations in hormone binding, and the free thyroxine equivalent and free triiodothyronine equivalent were calculated.16

CARBACHOL INHALATION TEST
The patients were studied under standardised conditions at the same time of day (10 am). sGaw was determined in a constant volume plethysmograph (Jaeger, Würzburg, FRG). Test aerosols of carbachol were generated by a Sandoz 1500 nebuliser (Sandoz, Nürnberg, FRG) attached to a dosimeter (APS system, Jaeger). The breath activated dosimeter delivered an aerosol bolus of about 100 ml a puff containing 7 μl of the carbachol solution. The delivery time was 0-6 seconds. The aerosol was inhaled by slowly breathing from functional residual capacity to total lung capacity with a breath hold time of two seconds. The dosage of carbachol was increased from a starting dose of five breaths of 0-125% carbachol until sGaw had fallen by 50% or until the maximum dose of 1260 μg was reached. The sequence of cumulative doses was 45, 90, 180, 360, 540, 720, 900, 1080, and 1260 μg. sGaw was determined two minutes after each dose and a mean value from five measurements was used. The inhalation tests were well tolerated by all subjects.

INTERSTUDY VARIATION OF BASELINE SGAW IN EUTHYROID CONTROL SUBJECTS
Baseline sGaw was measured in 11 euthyroid control subjects, aged 24–68 years, without pulmonary disease on two occasions separated by 62 days on average.

DATA ANALYSIS
The interstudy coefficients of variation of baseline sGaw were calculated for the control subjects and thyroid patients as the standard deviation expressed as a percentage of the mean for each pair of sGaw measurements. The interstudy coefficients of variation of baseline sGaw of the control subjects were compared with those of the thyroid patients by the two tailed F test. The cumulative dose producing a 35% fall in sGaw (PD35) was obtained from the log dose-response curve by linear regression analysis. Geometric mean PD35 values were calculated.17 The PD35 values were compared by the two tailed Wilcoxon signed rank test for paired observations after log transformation. A p value of less than 0.05 was considered statistically significant. The results are given as arithmetic means with standard deviations in parentheses unless it is stated otherwise.

Table 1 Mean (SD) concentrations of serum thyroid hormones when the patients were hypothyroid two weeks after triiodothyronine had been stopped and when they were subclinically hyperthyroid during thyroxine replacement treatment

<table>
<thead>
<tr>
<th></th>
<th>Hypothyroid</th>
<th>Hyperthyroid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total T4 (nmol/l)</td>
<td>15 (15)</td>
<td>164 (48)</td>
</tr>
<tr>
<td>FT4 (nmol/l)</td>
<td>0.20 (0.17)</td>
<td>4.0 (0.9)</td>
</tr>
<tr>
<td>FT3 (nmol/l)</td>
<td>0.57 (0.39)</td>
<td>1.93 (0.28)</td>
</tr>
<tr>
<td>FT3E (mU/l)</td>
<td>6 (4)</td>
<td>41 (6)</td>
</tr>
<tr>
<td>TSHE (mU/l)</td>
<td>46 (29-73)</td>
<td>0.03 (0.01-0.19)</td>
</tr>
<tr>
<td>TSHE (mU/l)</td>
<td>81 (54-121)</td>
<td>0.13 (0.04-0.44)</td>
</tr>
</tbody>
</table>

T4—thyroxine (normal 51–154 nmol/l); FT4E—free thyroxine equivalent (normal 1.5–4.12); T3—triiodothyronine (normal 1.23–2.76 nmol/l); FT3E—free triiodothyronine equivalent (normal 1.5–4.7); TSHE—basal thyroid stimulating hormone (normal 0.1–4 mU/l); TSH—thyroid stimulating hormone 20 minutes after intravenous administration of 200 μg of thyrotropin releasing hormone (normal 2–30 mU/l).

Results
THYROID STUDIES
The hormone data for the patients when hypothyroid and mildly hyperthyroid are shown in table 1. The mean daily dose of thyroxine required to cause suppression in the thyrotropin releasing hormone test was 200 (SD 53) μg (range 150–350 μg).

BASELINE PULMONARY FUNCTION
There was little difference in mean baseline pulmonary function values in the patients when they were hypothyroid and mildly hyperthyroid (table 2), and no change in mean baseline sGaw with change in thyroid state. Fairly pronounced variations in sGaw were seen between studies in individual patients (table 3). The interstudy coefficients of variation of baseline sGaw were greater in the thyroid patients (mean 14%, range 2–28%) than in the control group (mean 8%, range 1–18%) (p < 0.05).

CARBACHOL INHALATION TESTS
A PD35 value was obtained on all but one occasion. On this occasion the response was less than 35% after the maximum dose of carbachol had been given, so a value of 1260 μg was assigned. Geometric mean PD35 was lower in the patients when they were hypothyroid (97 μg) than when they were mildly hyperthyroid (192 μg) (p < 0.05; table 3).

Table 2 Mean (SD) baseline pulmonary function values when the patients were hypothyroid two weeks after triiodothyronine had been stopped and when they were subclinically hyperthyroid during thyroxine replacement treatment

<table>
<thead>
<tr>
<th></th>
<th>Hypothyroid</th>
<th>Hyperthyroid</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLC (l)</td>
<td>5.5 (1.4)</td>
<td>5.5 (1.4)</td>
</tr>
<tr>
<td>TLC (% pred)</td>
<td>95 (12)</td>
<td>96 (11)</td>
</tr>
<tr>
<td>RV (l)</td>
<td>1 (0.6)</td>
<td>1.2 (0.6)</td>
</tr>
<tr>
<td>RV (% pred)</td>
<td>63 (25)</td>
<td>70 (28)</td>
</tr>
<tr>
<td>FEV1 (1)</td>
<td>3.3 (2.0)</td>
<td>3.3 (2.0)</td>
</tr>
<tr>
<td>FEV1/VC (% pred)</td>
<td>93 (5)</td>
<td>96 (5)</td>
</tr>
<tr>
<td>sGaw (sa’kPa-‘)</td>
<td>1.35 (0.36)</td>
<td>1.41 (0.56)</td>
</tr>
<tr>
<td>sGaw (% pred)</td>
<td>110 (31)</td>
<td>117 (35)</td>
</tr>
</tbody>
</table>

TLC—total lung capacity; RV—residual volume; FEV1—forced expiratory volume in one second; VC—inspiratory vital capacity; sGaw—specific airways conductance; pred—percentage of predicted value.
### Table 3: Baseline specific airways conductance (sGaw) and carbachol dose producing a decrease in specific airways conductance by 25% (PD_{25}) when the patients were hypothyroid and subclinically hypothyroid.

<table>
<thead>
<tr>
<th>Patient No</th>
<th>sGaw (s⁻¹kPa)</th>
<th>PD_{25} (µg)</th>
<th>sGaw (s⁻¹kPa)</th>
<th>PD_{25} (µg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.13</td>
<td>157</td>
<td>0.78</td>
<td>&gt;1260*</td>
</tr>
<tr>
<td>2</td>
<td>1.42</td>
<td>44</td>
<td>0.82</td>
<td>165</td>
</tr>
<tr>
<td>3</td>
<td>1.02</td>
<td>80</td>
<td>1.06</td>
<td>181</td>
</tr>
<tr>
<td>4</td>
<td>0.75</td>
<td>150</td>
<td>0.87</td>
<td>1019</td>
</tr>
<tr>
<td>5</td>
<td>2.20</td>
<td>207</td>
<td>1.81</td>
<td>578</td>
</tr>
<tr>
<td>6</td>
<td>1.34</td>
<td>105</td>
<td>1.22</td>
<td>151</td>
</tr>
<tr>
<td>7</td>
<td>1.21</td>
<td>91</td>
<td>1.98</td>
<td>224</td>
</tr>
<tr>
<td>8</td>
<td>1.32</td>
<td>92</td>
<td>1.88</td>
<td>77</td>
</tr>
<tr>
<td>9</td>
<td>1.19</td>
<td>135</td>
<td>1.98</td>
<td>60</td>
</tr>
<tr>
<td>10</td>
<td>1.74</td>
<td>104</td>
<td>2.06</td>
<td>49</td>
</tr>
<tr>
<td>11</td>
<td>1.90</td>
<td>37</td>
<td>2.65</td>
<td>78</td>
</tr>
</tbody>
</table>

Geometric mean 97 192

*A PD_{25} of 1260 µg was used for calculating the geometric mean.

### Discussion

The results of this study show significantly higher PD_{25} values when the patients were mildly hyperthyroid than when they were hypothyroid, suggesting that bronchial reactivity is increased in hypothyroidism. This contrasts with observations in asthmatic patients, in whom hypothyroidism has been associated with a reduction in bronchial reactivity. The effects of hypothyroidism on the bronchial reactivity of non-asthmatic subjects are probably of no clinical relevance since none of our patients reported any respiratory symptoms when their thyroid state was altered.

Bronchial reactivity was assessed from the change in sGaw, a measurement that is more sensitive but less reproducible than indices obtained from a forced expiration. We did not use indices from a forced expiratory manoeuvre as a change in thyroid state may affect these indices by altering the maximum respiratory muscle power. MYopathy may also occur in acute hypothyroidism. Thyroid-sympathetic interaction cannot therefore explain our findings. Other mechanisms have been proposed to account for the link between thyroid function and bronchial reactivity. Hypothyroidism increases the conversion of hydrocortisone to its inactive 11-ketonic derivative and hypothyroidism decreases it. Houl and Moore suggested that hyperthyroidism worsens asthma by decreasing the pulmonary breakdown of prostaglandins, most probably because of decreased levels of the enzyme prostaglandin 15-hydroxydehydrogenase. Settipane et al suggested that hyperthyroidism causes an overall decrease in cyclic AMP and so aggravates asthma. We conclude that the net effect of these hormone related mechanisms on bronchial reactivity is different in the asthmatic and the non-asthmatic bronchial tree.

---


18 Freedman S. Lung volumes and distensibility, and maximum respiratory pressures in thyroid disease before and after treatment. Thorax 1978;33:785-90.


Effects of hypothyroidism on bronchial reactivity in non-asthmatic subjects.

S Wieshammer, F S Keck, A C Schäuffelen, H von Beauvais, H Seibold and V Hombach

Thorax 1990 45: 947-950
doi: 10.1136/thx.45.12.947

Updated information and services can be found at:
http://thorax.bmj.com/content/45/12/947

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/